23. Coggeshall RE, Lekan HA (1996) Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 364: 6–15. 24. Zhang X, Chen Y, Ikonomovic MD, Nathaniel PD, Kochanek PM, et al. (2006) Increased phosphorylation of protein kinase B and related substrates after traumatic brain injury in humans and rats. J Cereb Blood Flow Metab 26: 915–926. 25. Shapira M, Licht A, Milman A, Pick CG, Shohami E, et al. (2007) Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. Mol Cell Neurosci 34: 571–577. 26. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, et al. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793–803. 27. Ren M, Senatorov VV, Chen RW, Chuang DM (2003) Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A 100: 6210–6215. 28. Miller JS, Tallarida RJ, Unterwald EM (2010) Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice. Brain Res Bull 82: 184–187. 29. Colicos MA, Dash PK (1996) Apoptotic morphology of dentate gyrus granule cells following experimental cortical impact injury in rats: possible role in spatial memory deficits. Brain Res 739: 120–131. 30. Davidson G, Niehrs C (2010) Emerging links between CDK cell cycle regulators and Wnt signaling. Trends Cell Biol 20: 453–460. 31. Piao S, Lee SH, Kim H, Yum S, Stamos JL, et al. (2008) Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta- Catenin signaling. PLoS One 3: e4046. 32. Wu G, Huang H, Garcia AJ, He X (2009) Inhibition of GSK3 phosphorylation of beta-Catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One 4: e4926. 33. Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, et al. (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97: 11960–11965. 34. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785–789. 35. Neary JT, Kang Y (2006) P2 purinergic receptors signal to glycogen synthase kinase-3beta in astrocytes. J Neurosci Res 84: 515–524. 36. Stambolic V, Ruel L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664–1668. 37. Sutherland C, Leighton IA, Cohen P (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth- factor signalling. Biochem J 296(Pt 1): 15–19. 38. Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS (2005) Bench-to- bedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Crit Care 9: 66–75. 39. Soutar MP, Kim WY, Williamson R, Peggie M, Hastie CJ, et al. (2010) Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem 115: 974–983. 40. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175–1186. 41. Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173–189. 42. Facci L, Stevens DA, Skaper SD (2003) Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 14: 1467–1470. 43. Takadera T, Sakamoto Y, Ohyashiki T (2004) NMDA receptor 2B-selective antagonist ifenprodil-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons. Brain Res 1020: 196–203. 44. Takadera T, Ohyashiki T (2004) Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons. Eur J Pharmacol 499: 239–245. 45. Margulies S, Hicks R (2009) Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma 26: 925–939. 46. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 8455–8459. 47. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278: 33067–33077. Glycogen Synthase Kinase-3 and TBI 48. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/ threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96: 8745–8750. 49. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80: 589–597. 50. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, et al. (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28: 2576–2588. 51. Castro AA, Casagrande TS, Moretti M, Constantino L, Petronilho F, et al. (2009) Lithium attenuates behavioral and biochemical effects of neuropeptide S in mice. Peptides 30: 1914–1920. 52. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, et al. (2000) Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biol Psychiatry 48: 1–8. 53. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000) Lithium-induced increase in human brain grey matter. Lancet 356: 1241–1242. 54. Silverstone PH, Wu RH, O’Donnell T, Ulrich M, Asghar SJ, et al. (2003) Chronic treatment with lithium, but not sodium valproate, increases cortical N- acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psycho- pharmacol 18: 73–79. 55. Drevets WC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11: 240–249. 56. Aghdam SY, Barger SW (2007) Glycogen synthase kinase-3 in neurodegener- ation and neuroprotection: lessons from lithium. Curr Alzheimer Res 4: 21–31. 57. Atack JR, Cook SM, Watt AP, Ragan CI (1992) Measurement of lithium- induced changes in mouse inositol(1)phosphate levels in vivo. J Neurochem 59: 1946–1954. 58. Spiegelberg BD, Xiong JP, Smith JJ, Gu RF, York JD (1999) Cloning and characterization of a mammalian lithium-sensitive bisphosphate 39-nucleotidase inhibited by inositol 1,4-bisphosphate. J Biol Chem 274: 13619–13628. 59. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, et al. (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276: 31674–31683. 60. Zhu ZF, Wang QG, Han BJ, William CP (2010) Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Res Bull 83: 272–277. 61. Clark RS, Kochanek PM, Watkins SC, Chen M, Dixon CE, et al. (2000) Caspase-3 mediated neuronal death after traumatic brain injury in rats. J Neurochem 74: 740–753. 62. Colicos MA, Dash PK (1996) Apoptotic morphology of dentate gyrus granule cells following experimental cortical impact injury in rats: possible role in spatial memory deficits. Brain Res 739: 120–131. 63. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158: 100–106. 64. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, et al. (2011) Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494: 54–56. 65. Mora A, Sabio G, Gonzalez-Polo RA, Cuenda A, Alessi DR, et al. (2001) Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J Neurochem 78: 199–206. 66. Wraae O (1978) The pharmacokinetics of lithium in the brain, cerebrospinal fluid and serum of the rat. Br J Pharmacol 64: 273–279. 67. Lin D, Mok H, Yatham LN (2006) Polytherapy in bipolar disorder. CNS Drugs 20: 29–42. 68. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, et al. (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155: 567–572. 69. Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, et al. (2010) Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 5: e11383. 70. Grandjean EM, Aubry JM (2009) Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 23: 397–418. 71. Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5: 539–551. PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24648